心脉隆注射液治疗老年慢性心力衰竭的临床疗效及安全性分析  

Clinical effects and safety of Xinmailong injection in treatment of elderly patients with chronic heart failure

作　　者：仝峰[1] 司大妞[1] 乔雯雯[1] 陈建涛[1] Tong Feng;Si Daniu;Qiao Wenwen;Chen Jiantao(Department of Cardiovascular Medicine,Second People's Hospital of Jiaozuo,Jiaozuo 454000,China;不详)

机构地区：[1]焦作市第二人民医院心血管内科,焦作454000

出　　处：《中国循证心血管医学杂志》2021年第6期726-729,741,共5页Chinese Journal of Evidence-Based Cardiovascular Medicine

基　　金：河南省焦作市科技局项目(2016KY020)。

摘　　要：目的探讨心脉隆注射液治疗老年慢性心力衰竭(CHF)患者的临床疗效、安全性以及对可溶性生长刺激表达基因2蛋白(sST2)、心脏型脂肪酸结合蛋白(H-FABP)、超敏肌钙蛋白I(hs-TnI)的影响。方法选取2018年9月~2019年8月期间于焦作市第二人民医院心血管内科接受治疗的老年(≥60岁)CHF患者(左室射血分数≤40%)112例为研究对象,随机分为对照组和观察组(各组均为56例)。两组患者均接受西医常规抗心力衰竭(心衰)治疗,观察组在对照组基础上联合心脉隆注射液治疗。比较两组患者左心室射血分数(LVEF)、左室收缩末期内径(LVESd)、左室舒张末期内径(LVEDd)、sST2、H-FABP、hs-TnI、6分钟步行试验(6MWT)指标的变化及治疗的临床疗效、安全性。结果对照组和观察组患者治疗总有效率分别为83.93%和96.43%,观察组明显高于对照组(P<0.05)。治疗后,两组LVEF、LVESd、LVEDd以及6MWT距离均得到改善(P<0.05),且观察组患者LVEF和6MWT高于对照组,同时LVESd、LVEDd低于对照组(P<0.05)。此外,与治疗前相比,两组患者治疗后H-FABP、sST2、hs-TnI值均降低(P<0.05),且观察组患者H-FABP、sST2、hs-TnI值较对照组降低更明显(P<0.05)。对照组患者复合性心脏事件(CCEs)发生率12.50%(7/56),观察组为3.57%(2/56),差异无统计学意义(P>0.05)。两组均未出现严重药物相关不良反应。结论心脉隆注射液联合西医常规抗心衰方案对治疗老年CHF效果确切,能有效改善患者心功能,降低sST2、H-FABP、hs-TnI水平,优化心肌供血,且安全性良好,该方案值得临床推广。Objective To investigate the clinical efficacy,safety,and effects on soluble growth stimulator expressed gene 2 protein(sst2),cardiac fatty acid binding protein(H-FABP),and hypersensitivity troponin I(HS TnI)in the treatment of elderly patients with chronic heart failure(CHF).Methods A total of 112 elderly(≥60 years old)patients with CHF(left ventricular ejection fraction≤40%)who were treated in the Department of cardiovascular medicine of the second people's Hospital of Jiaozuo City between September 2018 and August 2019 were selected for the study and randomly divided into control(n=56 patients)and observation(n=56 patients)groups.Patients in both groups were treated with conventional anti HF therapies by western medicine,and patients in the observation group were treated with combined cardiovascular brodifacoum injection on a control basis.Changes in left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDd),sST2,H-FABP,HS TnI,indexes of 6-minute walk test(6MWT)and clinical efficacy and safety of treatments were compared between the two groups.Results The overall response rate of the treatment for patients in the control and observation groups was 83.93%and 96.43%,respectively,and it was significantly higher in the observation group than in the control group(P<0.05).After treatment,LVEF,LVESD,LVEDd as well as 6MWT distance improved in both groups(P<0.05),and the LVEF and 6MWT were higher in the observation group than in the control group,along with lower LVESD and LVEDd than in the control group(P<0.05).In addition,H-FABP,sst2,and HS TnI values were decreased in both patients after treatment compared with before treatment(P<0.05),and in the observation group,H-FABP,sst2,and HS TnI values were decreased more significantly than in the control group(P<0.05).The incidence of composite cardiac events(CCEs)was 12.50%(7/56)in the control group and 3.57%(2/56)in the observation group,which was not significantly different(P>0.05).No serious

关 键 词：慢性心力衰竭 心脉隆注射液 sST2 H-FABP hs-TnI 

分 类 号：R541.61[医药卫生—心血管疾病]